Natera (NASDAQ:NTRA) Stock Price Target Lowered at JPMorgan Chase & Co.

Natera (NASDAQ:NTRA) had its target price cut by JPMorgan Chase & Co. from $460.00 to $405.00 in a research report report published on Friday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Several other analysts also recently issued reports on NTRA. Wells Fargo & Company raised their price objective on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Guggenheim increased their price target on Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. UBS Group raised their price target on Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Robert W. Baird set a $348.00 price objective on Natera in a research report on Friday, August 7th. Finally, BTIG Research increased their target price on Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research note on Tuesday, October 27th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $391.69.

Natera Stock Down 14.6%

NTRA traded down $53.09 during trading on Friday, reaching $310.67. The company had a trading volume of 5,775,619 shares, compared to its average volume of 1,603,151. The stock has a market cap of $44.78 billion, a P/E ratio of -272.52 and a beta of 1.55. The business has a 50 day simple moving average of $380.25 and a 200-day simple moving average of $269.68. Natera has a 52 week low of $181.00 and a 52 week high of $437.41.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm had revenue of $793.98 million for the quarter, compared to analysts’ expectations of $707.54 million. During the same period in the previous year, the firm earned ($0.64) earnings per share. The firm’s quarterly revenue was up 34.1% compared to the same quarter last year. As a group, equities research analysts expect that Natera will post -1.14 EPS for the current fiscal year.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 15,160 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40. Following the transaction, the insider directly owned 110,859 shares in the company, valued at $36,238,698.51. This trade represents a 12.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 1,906 shares of Natera stock in a transaction on Friday, October 30th. The shares were sold at an average price of $425.55, for a total value of $811,098.30. Following the sale, the chief financial officer directly owned 46,574 shares of the company’s stock, valued at approximately $19,819,565.70. This trade represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 53,573 shares of company stock worth $19,856,400 in the last ninety days. 5.05% of the stock is owned by company insiders.

Institutional Trading of Natera

Several institutional investors and hedge funds have recently made changes to their positions in NTRA. BlackRock Inc. bought a new position in Natera during the 2nd quarter worth about $2,962,770,000. Aberdeen Group plc raised its holdings in shares of Natera by 26,462.7% in the 3rd quarter. Aberdeen Group plc now owns 1,398,794 shares of the medical research company’s stock valued at $578,136,000 after purchasing an additional 1,393,528 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock worth $238,334,000 after purchasing an additional 11,793 shares during the period. Maverick Capital Ltd. lifted its position in shares of Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after purchasing an additional 227,605 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Natera by 10.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after purchasing an additional 80,440 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
• Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
• Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
• Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results

Natera Company Profile

Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

The company also provides Prospera, a molecular test used to help assess organ transplant rejection.